drugset / Trial / NCT00456833

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

NCT00456833

Phase 1 Completed 248 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

Timeline

Start
2005-06
Primary completion
2011-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 5 mg
Comparator Erlotinib Small molecule 150 mg